Strata Critical Medical, Inc. (SRTA) Earnings

Management highlights

- Financial and Cash Flow Results * Q2 2026 generated $5.7 million in operating cash flow and $2.9 million in free cash flow, marking the second consecutive quarter of positive cash generation, with stronger cash flow expected in H2 2026. * Adjusted EBITDA was $7.9 million (up from $6.4 million in Q1 2026), with adjusted EBITDA margin rising 140 basis points sequentially to 10.9%. - Capital Deployment & M&A * The company completed three bolt-on strategic acquisitions in Q2 2026 at mid-single-digit multiples, ahead of schedule for its capital deployment plan. Acquisitions include two regional perfusion services (Louisville Perfusion Services, Ohio Valley Perfusion Associates) and Heart and Lung Transplant National Recovery Program, expanding the company's national footprint, scale, and competitive position in organ transplant. * The company signed an agreement to transition Statline's Transplant Center organ placement customer relationships over 12 months, creating long-term attachment points for up to 8 new customers with a maximum total potential fee under $1 million. * Year-to-date acquisitions add more than $20 million of annual revenue and $6.3 million of projected annualized EBITDA; acquisition activity is expected to slow in H2 2026, with a strong pipeline of opportunities remaining. - Industry & Operational Updates * Industry DCD donor volumes saw a low single-digit sequential increase in Q2 2026, and year-over-year growth is expected in H2 2026. NRP penetration of DCD donors rose to 59% from 57% in Q1 2026, with NRP shown to increase usable organs per DCD donor by ~50% on average. * Strata operates a differentiated captive logistics network with 35 aircraft (10 owned, 25 100% dedicated), 55 ground vehicles, 24/7 operations center, and an equipment-agnostic strategy compatible with all approved and upcoming machine perfusion devices; no single device represents more than a mid-single-digit percentage of total air trips. * The expanded geographic footprint reduces customer travel costs and increases clinician productivity by cutting down on unnecessary air travel.

Guidance

- Full year 2026 revenue guidance was raised to $285–$295 million, up from the prior range of $260–$275 million. Full year 2026 adjusted EBITDA guidance was raised to $33–$35 million, up from the prior range of $29–$33 million. - Free cash flow before aircraft acquisitions is maintained at $15–$22 million for 2026, as higher adjusted EBITDA is offset by non-recurring acquisition costs and working capital build from faster transplant clinical growth. - Q3 2026 logistics revenue is expected to decline a high single-digit percentage sequentially, impacted by the 3% customer volume headwind and typical summer industry seasonality; logistics revenue is expected to recover to near Q2 2026 levels by Q4 2026. - Logistics gross margin is expected to gradually improve to a range of 18.5%–20% in H2 2026, with restoration to the 20% 2027 target confirmed. - Clinical revenue is expected to grow ~20% sequentially in Q3 2026 (driven by full quarter contributions from Q2 acquisitions), followed by mid-single-digit sequential growth in Q4 2026. Clinical gross margins are expected to rise to 27%–28% in H2 2026. - Adjusted SG&A is expected to remain in the low $9 million range for the remainder of 2026.

Segment performance

Strata Critical Medical's total Q2 2026 revenue grew 60.7% year-over-year to $72.5 million, with gross profit growing 68.9% year-over-year to $15.2 million and overall gross margin of 21% (up 100 basis points YoY). 1. Logistics Segment: - Year-over-year revenue growth was 6.9%, with a 1% sequential increase from Q1 2026. Gross margin fell to 18.4% in Q2 2026 from 19.3% in Q1 2026. Excluding fuel surcharge impacts, gross margin was 19%. - Revenue contribution was approximately 66.5% of total Q2 2026 revenue. 2. Clinical Segment: - Sequential revenue increased 22.6% to $24.3 million from $19.8 million in Q1 2026; organic sequential growth (excluding Q2 acquisitions) was 15.1%, driven by 23.8% growth in transplant clinical revenue and 6.5% growth in other clinical revenue. - Sequential gross profit increased 27.8% to $6.3 million from $5 million in Q1 2026, with gross margin rising to 26.1% from 25% in Q1 2026. - Revenue contribution was approximately 33.5% of total Q2 2026 revenue, with the company expecting this to rise to ~40% of revenue in the second half of 2026.

Risks & headwinds

- A single non-exclusive customer significantly reduced flying volumes for one transplant program starting in Q2 2026, creating a 3% headwind to logistics revenue that will have full impact in Q3 2026; while management expects the impact to be unique to this customer and mitigated by Q4 2026, it creates short-term volatility. - Logistics gross margin is inherently volatile due to unpredictable factors including unscheduled aircraft maintenance; Q2 2026 saw higher than expected unscheduled maintenance costs and a shift to lower-margin third-party ground vehicles, pressuring margins below target. - Fuel prices above contract thresholds can pressure gross margins for a small number of logistics contracts where fuel pass-through mechanisms are capped or activate at higher price levels. - Ongoing industry volume seasonality creates quarterly revenue volatility for logistics, with typical Q3 declines in heart, liver, and lung transplant volumes.

Analyst Q&A

• Q: Analyst asks whether Strata is gaining machine perfusion market share despite flat industry volume, and asks for an update on logistics performance. /

  A: Management confirms Strata is gaining share, pointing to strong sequential organic clinical growth and continuing sequential increases in NRP penetration of DCD donors. Strata is also growing adoption of its third-party surgical recovery services even for brain dead recoveries, as its model of deploying local surgeons before activating aircraft reduces customer costs for uncertain recoveries.

• Q: Analyst asks for more detail on how Strata reduces dry run costs for customers, and which organs have the highest dry run rates. /

  A: Management notes dry run risk is highly variable based on donor specifics, and Strata works with customers to evaluate risk case-by-case. The key cost saving comes from deploying local surgeons first, only activating aircraft once organs are confirmed viable, allowing customers to pursue higher-risk organs that they would otherwise pass on, with far lower downside cost.

• Q: Analyst asks to break down the contributions of Q2 outperformance vs acquisitions to the 2026 guidance increase. /

  A: Management confirms Q2 2026 acquisitions add approximately $11.5–$12 million to 2026 revenue and ~$3.5 million to 2026 adjusted EBITDA. The remainder of the guidance increase comes from outperformance in Strata's existing base business, with net positive puts and takes across the business leading to the upward guidance revision.

• Q: Analyst asks for more detail on the initiatives to restore logistics gross margin to the 20% target, and asks how durable these improvements are. /

  A: Management explains the structural improvements include proactively removing low-margin aircraft from the fleet and replacing them with more efficient dedicated lift from higher-performing operators, and reallocating owned aircraft to increase flight hours (spreading fixed costs over more volume). Additional actions to improve ground vehicle and driver utilization will restore ground margins to previous levels in H2 2026, with many changes already implemented in July 2026.